Researchers find new immunosuppressive cells affect anti-tumor immune response
Chinese and foreign researchers have recently discovered that a new type of immunosuppressive cells can affect the anti-tumor immune response, thereby affecting the effectiveness of immunotherapy in some tumor patients.
According to Prof. Zhu Bo, Department of Oncology, Xinqiao Hospital，In recent years, the tumor immunotherapy represented by the pd-1 / pd-l1 antibody has achieved a significant breakthrough, and has become one of the important means of clinical tumor treatment. However, in clinical practice, the efficiency of pd-1 / pd-L1 antibody to treat tumors is only between 20% and 30%. In addition to the fact that tumor cells can constantly evolve to avoid immune recognition, tumor patients can also produce a variety of immunosuppressive cells, such as myeloid source inhibitory cells, which affect the effect of immunotherapy.
Scientists have been trying to explore other immunosuppressive cells in tumor patients. Recently, professor zhu bo's team, together with Chinese and foreign scientific research institutions, found a new type of immunosuppressive cells derived from red precursor cells in the spleen, liver and peripheral blood of mice with tumor and the peripheral blood of tumor patients. This cell inhibits the CD8+ t-cell-mediated immune response by producing reactive oxygen species (ROS), leading to decreased antiviral/bacterial and anti-tumor immune response function in tumor patients.
It is understood that normal red precursor cells are supposed to differentiate into normal red blood cells, but the cells found by professor zhu bo's team not only fail to differentiate normally, but also produce a strong ability of immune suppression, making normal immune cells unable to effectively kill tumor cells and remove pathogens in the body. This study provides a new way to further understand the mechanism of tumor immunosuppression and improve the efficacy of immunotherapy in tumor patients.
According to Prof. Zhu Bo, Department of Oncology, Xinqiao Hospital，In recent years, the tumor immunotherapy represented by the pd-1 / pd-l1 antibody has achieved a significant breakthrough, and has become one of the important means of clinical tumor treatment. However, in clinical practice, the efficiency of pd-1 / pd-L1 antibody to treat tumors is only between 20% and 30%. In addition to the fact that tumor cells can constantly evolve to avoid immune recognition, tumor patients can also produce a variety of immunosuppressive cells, such as myeloid source inhibitory cells, which affect the effect of immunotherapy.
Scientists have been trying to explore other immunosuppressive cells in tumor patients. Recently, professor zhu bo's team, together with Chinese and foreign scientific research institutions, found a new type of immunosuppressive cells derived from red precursor cells in the spleen, liver and peripheral blood of mice with tumor and the peripheral blood of tumor patients. This cell inhibits the CD8+ t-cell-mediated immune response by producing reactive oxygen species (ROS), leading to decreased antiviral/bacterial and anti-tumor immune response function in tumor patients.
It is understood that normal red precursor cells are supposed to differentiate into normal red blood cells, but the cells found by professor zhu bo's team not only fail to differentiate normally, but also produce a strong ability of immune suppression, making normal immune cells unable to effectively kill tumor cells and remove pathogens in the body. This study provides a new way to further understand the mechanism of tumor immunosuppression and improve the efficacy of immunotherapy in tumor patients.
